Simple Blood Test Could Determine Best Treatment Option for Advanced Prostate Cancer, Study Says

Simple Blood Test Could Determine Best Treatment Option for Advanced Prostate Cancer, Study Says
A blood test that examines circulating tumor cells for the presence of the AR-V7 protein could help determine if a patient with advanced prostate cancer would fare better with chemotherapy or hormone therapy, according to researchers. Their study, “Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer,” was published in the journal JAMA Oncology. Medicines that target the androgen receptor, like Zytiga (enzalutamide) and Xtandi (abiraterone), are widely used for the treatment of advanced prostate cancer. But as happens with many medications, tumors often develop a resistance to such therapies. In some cases, resistance develops when cells produce a variant of the androgen receptor, called AR-V7, that lacks the domain targeted by current androgen receptor inhibitors. When a patient is first diagnosed with metastatic castration-resistance prostate cancer (MCRPC), the preferred treatment involves androgen receptor inhibitors. But if a patient fails a first-line treatment with these inhibitors, there is no guarantee he'll respond to a second inhibitor. In such cases, researchers need biomarkers that help them select which patients should receive a second androgen receptor inhib
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *